Neurocrine Biosciences Inc. (NASDAQ:NBIX) – Research analysts at Oppenheimer Holdings issued their Q4 2016 earnings per share estimates for shares of Neurocrine Biosciences in a report released on Monday. Oppenheimer Holdings analyst J. Olson anticipates that the brokerage will post earnings per share of ($0.54) for the quarter. Oppenheimer Holdings currently has a “Market Perform” rating and a $55.00 target price on the stock. Oppenheimer Holdings also issued estimates for Neurocrine Biosciences’ Q2 2017 earnings at ($0.56) EPS, FY2018 earnings at $0.64 EPS and FY2019 earnings at $0.55 EPS.

Several other analysts have also weighed in on the company. Citigroup Inc. began coverage on Neurocrine Biosciences in a research note on Tuesday. They issued a “market perform” rating and a $55.00 price objective on the stock. They noted that the move was a valuation call. Jefferies Group reaffirmed a “sell” rating and issued a $61.00 price objective on shares of Neurocrine Biosciences in a research note on Tuesday, November 8th. BMO Capital Markets reaffirmed a “buy” rating and issued a $72.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, November 3rd. Barclays PLC reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, November 3rd. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $96.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, November 3rd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $66.92.

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ:NBIX) opened at 50.31 on Wednesday. The company has a 50 day moving average price of $46.84 and a 200 day moving average price of $48.11. The firm’s market capitalization is $4.37 billion. Neurocrine Biosciences has a 12 month low of $31.25 and a 12 month high of $58.46.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.57) by $0.14. During the same period last year, the business earned ($0.40) earnings per share. The business’s revenue was up .0% on a year-over-year basis.

In other Neurocrine Biosciences news, insider Malcolm Lloyd-Smith sold 9,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Thursday, September 1st. The stock was sold at an average price of $50.00, for a total value of $450,000.00. Following the completion of the sale, the insider now directly owns 9,000 shares in the company, valued at $450,000. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Christopher Flint Obrien sold 25,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $52.84, for a total value of $1,321,000.00. Following the completion of the sale, the insider now owns 30,044 shares of the company’s stock, valued at $1,587,524.96. The disclosure for this sale can be found here. 4.80% of the stock is owned by company insiders.

Large investors have recently modified their holdings of the company. Bank of New York Mellon Corp increased its stake in shares of Neurocrine Biosciences by 238.4% in the third quarter. Bank of New York Mellon Corp now owns 1,406,038 shares of the company’s stock worth $71,202,000 after buying an additional 990,488 shares during the last quarter. Alliancebernstein L.P. boosted its stake in shares of Neurocrine Biosciences by 650.2% in the second quarter. Alliancebernstein L.P. now owns 1,104,515 shares of the company’s stock worth $50,200,000 after buying an additional 957,289 shares during the period. Baker BROS. Advisors LP purchased a new stake in shares of Neurocrine Biosciences during the third quarter worth approximately $45,344,000. Senator Investment Group LP purchased a new stake in shares of Neurocrine Biosciences during the second quarter worth approximately $38,632,000. Finally, American Century Companies Inc. boosted its stake in shares of Neurocrine Biosciences by 890.6% in the second quarter. American Century Companies Inc. now owns 821,527 shares of the company’s stock worth $37,338,000 after buying an additional 738,598 shares during the period. Institutional investors and hedge funds own 96.30% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/25/neurocrine-biosciences-inc-forecasted-to-earn-q4-2016-earnings-of-0-54-per-share-nbix.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

5 Day Chart for NASDAQ:NBIX

Receive News & Stock Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related stocks with our FREE daily email newsletter.